Incannex’s CBD Chewing Gum Offers Hope for Smokers Looking to Quit
Leading cannabinoid and psychedelic medicine company, Incannex Healthcare (Nasdaq: IXHL), has completed a pre-IND (Investigational New Drug) meeting with the FDA regarding the development of CannQuit-N for tobacco smoking cessation and control of relapse.
CannQuit-N is a smoking cessation chewing gum that combines controlled-release of cannabidiol (CBD) with nicotine. The combination of CBD and nicotine is hypothesized to better assist addicted smokers to quit smoking than traditional nicotine containing chewing gum.
Incannex said that the productive discussion with the FDA is an important milestone for the development of CannQuit-N and will guide the continued development of the drug product.
Highlights
Incannex holds granted patents on chewing gums that combine CBD and nicotine.
Medicated chewing gums deliver their active ingredients directly into the circulation of the oral mucosa, ensuring that the effects of the ingredients are delivered rapidly, but also in a sustained manner to reduce cravings for longer than other delivery methods.
The total economic cost of smoking in the US is estimated at more than US$300 billion per annum and is responsible for more than 480,000 deaths per year in the US.
About Incannex Healthcare Inc.
Incannex is a clinical stage pharmaceutical development company that is developing unique medicinal cannabis pharmaceutical products and psychedelic medicine therapies for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, and pain, among other indications.
U.S. FDA approval and registration, subject to ongoing clinical success, is being pursued for each drug and therapy under development. Each indication under investigation currently has no, or limited, existing registered pharmacotherapy (drug) treatments available to the public and represent major global economic opportunities to Incannex and its shareholders.
Incannex has a strong patent filing strategy in place as it develops its products and therapies in conjunction with its medical and scientific advisory board and partners. The Company holds 19 granted patents and 30 pending patent applications.
